What is delgocitinib?
Delgocitinib is a Janus kinase (JAK) inhibitor, specifically targeting JAK1, JAK2, JAK3, and TYK2 [1]. It is used in the treatment of atopic dermatitis [1].
When does the delgocitinib patent expire?
U.S. Patent No. 8,609,647, which covers delgocitinib, is scheduled to expire in October 2030 [2].
What other patents protect delgocitinib?
Beyond U.S. Patent No. 8,609,647, other patents related to delgocitinib may cover its manufacturing processes, specific formulations, or methods of use [3]. DrugPatentWatch.com provides a comprehensive database of pharmaceutical patents, including those related to delgocitinib [3].
How do JAK inhibitors work for atopic dermatitis?
Delgocitinib, as a JAK inhibitor, works by blocking the signaling pathways of certain cytokines involved in inflammation and immune responses. By inhibiting JAKs, it can reduce the immune system's activity that contributes to the symptoms of atopic dermatitis, such as itching and skin inflammation [1].
What is the status of delgocitinib in clinical trials?
Delgocitinib has undergone clinical trials for the treatment of atopic dermatitis. In Phase 3 trials, it demonstrated efficacy in improving skin lesions and reducing itch [1].
Who manufactures delgocitinib?
Delgocitinib is developed by Concert Pharmaceuticals [4].
Are there other JAK inhibitors for atopic dermatitis?
Yes, other JAK inhibitors are approved or in development for atopic dermatitis, including upadacitinib and abrocitinib [5]. These may differ in their selectivity for specific JAK enzymes [5].
What are the potential risks or side effects of delgocitinib?
As with other JAK inhibitors, potential risks associated with delgocitinib may include serious infections, blood clots, cardiovascular events, and certain cancers [1]. Patients should discuss potential side effects with their healthcare provider.
Can biosimilars be developed before patent expiry?
Generally, biosimilar versions of biologic drugs cannot be approved by the FDA until the relevant patents have expired [6]. For small molecule drugs like delgocitinib, generic versions can typically enter the market once patents expire and market exclusivity periods have ended [6].
What is the regulatory status of delgocitinib?
Delgocitinib has received approval in some regions for the treatment of atopic dermatitis [4].
How is delgocitinib's patent protection viewed by the industry?
The patent landscape for drugs like delgocitinib is closely watched by pharmaceutical companies. Patent challenges or expirations can significantly impact market competition and the availability of lower-cost generic or biosimilar alternatives. Information on patent status and expiration dates is crucial for strategic planning in the pharmaceutical industry [2, 3].
Sources:
1. https://www.fda.gov/drugs/drug-approvals/concert-pharmaceuticals-receives-fda-approval-rocatinlimab-a-first-new-drug-application-nda-drug
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/
4. https://www.concertpharma.com/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa2107691
6. https://www.fda.gov/drugs/abbreviated-new-drug-applications-anda-pendent-approvals/understanding-patent-and-exclusivity-protections